Weekly Investment Analysts’ Ratings Updates for Aquestive Therapeutics (AQST)

A number of firms have modified their ratings and price targets on shares of Aquestive Therapeutics (NASDAQ: AQST) recently:

• 10/17/2025 – Aquestive Therapeutics was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/9/2025 – Aquestive Therapeutics had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 10/9/2025 – Aquestive Therapeutics had its price target raised by analysts at JMP Securities from $9.00 to $12.00. They now have a “market outperform” rating on the stock.
• 10/8/2025 – Aquestive Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Aquestive Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/8/2025 – Aquestive Therapeutics had its price target raised by analysts at Oppenheimer Holdings, Inc. from $7.00 to $8.00. They now have an “outperform” rating on the stock.
• 9/3/2025 – Aquestive Therapeutics was upgraded by analysts at Lifesci Capital to a “strong-buy” rating.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Carl N. Kraus sold 20,272 shares of the firm’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $7.00, for a total value of $141,904.00. Following the transaction, the insider owned 282,475 shares in the company, valued at approximately $1,977,325. This trade represents a 6.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Peter E. Boyd sold 15,000 shares of the firm’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $5.30, for a total value of $79,500.00. Following the completion of the transaction, the insider owned 288,323 shares in the company, valued at $1,528,111.90. The trade was a 4.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 276,770 shares of company stock worth $1,692,203. Company insiders own 7.85% of the company’s stock.

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.